Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
We carried out a population-based study on low-grade diffuse gliomas in the Canton of Zurich, Switzerland (population 1.16 million). From 1980 to 1994, 987 astrocytic and oligodendroglial tumors were diagnosed, of which 122 (12.4%) were low-grade (WHO grade II). The incidence rates adjusted to the World Standard Population, per million population per year, were 2.28 for low-grade diffuse astrocytomas, 0.89 for oligoastrocytomas, and 2.45 for oligodendrogliomas. The survival rate (mean follow-up 7.5+/-4.8 years) was highest for patients with oligodendroglioma (78% at 5 years, 51% at 10 years), followed by those with oligoastrocytoma (70% at 5 years, 49% at 10 years) and fibrillary astrocytoma (65% at 5 years, 31% at 10 years). Survival of patients with gemistocytic astrocytoma was poor, with survival rates of 16% at 5 years and 0% at 10 years. Younger patients (<50 years) survived significantly longer than older patients (>50 years; P=0.013). DNA sequencing, performed in 84% of cases, revealed that TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but were infrequent (13%) in oligodendrogliomas. The presence of TP53 mutations was associated with shorter survival of patients with low-grade diffuse gliomas (log-rank test; P=0.047), but when each histological type was analyzed separately, an association was observed only for oligoastrocytoma ( P=0.05). Loss on 1p and 19q were assessed by quantitative microsatellite analysis in 67% of cases. These alterations were frequent in oligodendrogliomas (1p, 57%; 19q, 69%), less common in oligoastrocytomas (1p, 27%; 19q, 45%), rare in fibrillary astrocytomas (1p, 7%; 19q, 7%), and absent in gemistocytic astrocytomas. None of these alterations were predictive of survival. These results establish the frequency of key genetic alterations in low-grade diffuse gliomas at a population-based level. Multivariate Cox's regression analysis indicates that only age and histological type, but not genetic alterations, are significant predictive factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epidemiological studies demonstrate that “hot spot” codon mutations are common in GBM (specifically, 248 and 273), with higher rates in secondary GBM, suggesting that the acquisition of TP53 mutations may differ between primary and secondary GBM [88,89].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [89]
Citations
Cites
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610 · cited 1×
“For anaplastic oligodendrogliomas, it is well established that the presence of LOH 1p/19q is a significant predictor of susceptibility to chemotherapy and better survival of patients [3, 6 ]; however, for WHO grade-II oligodendrogliomas, the data are less clear.”
BackgroundOhshima, H., & Bartsch, H. (1994) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/0027-5107(94)90245-3 · Cited by 1,055 · cited 1×
“This occurs spontaneously or is mediated through the action of oxygen radicals or of nitric oxide produced by nitric oxide synthase in conditions of chronic inflammation [ 20 ].”
BackgroundPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955 · cited 1×
“survival of patients with low-grade diffuse glioma in the present study and in previous clinical trials [ 22 , 30], poor survival of gemistocytic astrocytoma patients may be due, at least in part, to old age of the patients.”
ResultSmith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Self-citationOligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro-Oncology
Reifenberger, G., & Louis, D. N. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.2.111 · Cited by 296
A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma
Burkhard, C., Di Patre, P.-L., Schüler, D., Schüler, G., Yaşargil, M. G., Yonekawa, Y., Lütolf, U. M., Kleihues, P., & Ohgaki, H. (2003) · Journal of Neurosurgery · doi:10.3171/jns.2003.98.6.1170 · Cited by 279 · cited 2×
“This study was part of a population-based analysis of patients who were diagnosed with an astrocytic and/or oligodendroglial tumor (total 987 cases) in the Canton of Zurich (population, approximately 1.16 million) during the 15-year period from 1980 to 1994 [ 5 ].”
BackgroundMethodInfluentialSelf-citationBuckner, J. C., Gesme, D., O’Fallon, J. R., Hammack, J. E., Stafford, S., Brown, P. D., Hawkins, R., Scheithauer, B. W., Erickson, B. J., Levitt, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.023 · Cited by 249 · cited 1×
“Buckner et al. [ 4 ] carried out phase-II trials of PCV as initial therapy for 31 patients with low-grade oligodendroglioma or oligoastrocytoma and observed that LOH 1p/19q was not associated with response to PCV.”
Nakamura, M. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1715 · Cited by 248 · cited 1×
“As an alternative, our previous finding of a significant correlation between TP53 mutations and promoter methylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) gene in low-grade diffuse astrocytomas suggests the possible involvement of DNA alkylation at the O 6 -position of guanine [ 16 ].”
ResultMolecular Genetic Evidence for Subtypes of Oligoastrocytomas
MAINTZ, D., FIEDLER, K., KOOPMANN, J., ROLLBROCKER, B., NECHEV, S., LENARTZ, D., STANGL, A. P., LOUIS, D. N., SCHRAMM, J., WIESTLER, O. D., et al. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00003 · Cited by 247
Cited by
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
Self-citationOhgaki, H., & Kleihues, P. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.479 · Cited by 1,381
“Except for 2 cases, TP53 mutation and LOH 19q were mutually exclusive in low-grade gliomas and there was not a single case with both TP53 mutation and LOH 1p (7).”
BackgroundMethodResultInfluentialSelf-citationGenetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
“This is surprising because in hospital-based studies (2, 23) and in this population-based study, the incidence of low-grade or anaplastic gliomas in male patients was similar to or higher than in female patients ( 21 ).”
BackgroundResultInfluentialSelf-citationEpidemiology and etiology of gliomas
Ohgaki, H., & Kleihues, P. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-0991-y · Cited by 1,252
Self-citationThe Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
“In addition to frequent IDH1/2 mutations, about 60% of diffuse astrocytomas carry a TP53 mutation, while oligodendrogliomas show frequent 1p/19q loss (~70%) (11,29-33).”
BackgroundSelf-citation
Metadata
- Authors
- Okamoto, Y., Di Patre, P.-L., Burkhard, C., Horstmann, S., Jourde, B., Fahey, M., Schüler, D., Probst-Hensch, N. M., Yasargil, M. G., Yonekawa, Y., Lütolf, U. M., Kleihues, P., & Ohgaki, H.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- Kanton Zürich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Ohgaki, Hiroko
- Venue
- Acta Neuropathologica
- Published
- 2004-04-28
- Volume
- 108
- Issue
- 1
- Pages
- 49-56
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2059995145
- Cited by
- 330
- References
- 32
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 16 · 2022: 16 · 2021: 10 · 2020: 7 · 2019: 7 · 2018: 22 · 2017: 15 · 2016: 12 · 2015: 22 · 2014: 20 · 2013: 23 · 2012: 24
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Digital Commons - East Tennessee State University (East Tennessee State University) (submittedVersion)
- Swinburne figshare (Swinburne University of Technology) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Foundation for Promotion of Cancer Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- diffuse astrocytoma, oligodendroglioma, oligoastrocytoma, fibrillary astrocytoma, gemistocytic astrocytoma, incidence, survival, TP53 mutation, 1p/19q codeletion, loss of heterozygosity, DNA sequencing, microsatellite analysis, age and survival
- MeSH terms
- Age Factors, Aged, Astrocytoma, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, DNA Mutational Analysis, Exons, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mutation, Oligodendroglioma, Retrospective Studies, Sex Factors, Incidence, Survival Rate, Multivariate Analysis, Tumor Suppressor Protein p53, Neurosurgical Procedures, Loss of Heterozygosity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. https://app.cochat.ai/papers/10.1007/s00401-004-0861-z
- The paper
- Okamoto, Y., Di Patre, P.-L., Burkhard, C., Horstmann, S., Jourde, B., Fahey, M., Schüler, D., Probst-Hensch, N. M., Yasargil, M. G., Yonekawa, Y., Lütolf, U. M., Kleihues, P., & Ohgaki, H. (2004). Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathologica. https://doi.org/10.1007/s00401-004-0861-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.